LearnGlossaryMarketStocksSuperinvestorsSign in

CLGN

CollPlant Biotechnologies Ltd.

Healthcare · $5M market cap

Verdict

We can't put a fair value on CLGN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-15.0% a year✗
Sales growth6.9% a year✗
Free cash flow growth—?
Return on invested capital-24.1%✗

Follow CLGN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Abelis Bar Berta

VP Legal · 2026-09-03

Award

201,141 shares

Rotem Eran

Deputy CEO and CFO · 2026-09-03

Award

510,372 shares

About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works